Abstract
Background: The most important investigations since the first publication on opiorphin, in 2006, are summarized in this review. Opiorphin is a human endogenous pentapeptide (Gln-Arg-Phe-Ser-Arg) which inhibits both the Neutral EndoPeptidase (NEP) and aminopeptidase N (AP-N), protecting enkephalins from degradation by these ectopeptidases, thus activating endogenous enkephalin-related opioid pathways.
Objective: In this review we highlight the in vitro and in vivo effects of opiorphin.
Results: We examine in detail the structure-activity relationship studies addressed in order to identify the amino acids of opiorphin sequence required to functional interactions with its targets and to design its metabolically stable analogs. The modulation of emotionalrelated behaviors and effects on smooth muscle motility including their resulting therapeutic implication are also analysed. In addition, the in vitro potency of opiorphin and its metabolically stable analogs on opioid receptor binding by enkephalin-related peptides are also summarized. Finally, quantitative or semiquantitative analytical methods of opiorphin on various biological samples are cited.
Conclusion: The advantages and difficulties of therapeutic applications of opiorphin peptide and its synthetic derivatives are discussed.
Keywords: Opiorphin, AP-N and NEP enkephalinases, enkephalins, analgesia, opioid receptors, emotional behaviors, smooth muscle motility, analytical methods.
Graphical Abstract
Current Bioactive Compounds
Title:Human Opiorphin an Endogenous Inhibitor of Enkephalin-Inactivating Ectopeptidases that Displays Antinociception: A Review
Volume: 12 Issue: 4
Author(s): Maria Wollemann and Catherine Rougeot
Affiliation:
Keywords: Opiorphin, AP-N and NEP enkephalinases, enkephalins, analgesia, opioid receptors, emotional behaviors, smooth muscle motility, analytical methods.
Abstract: Background: The most important investigations since the first publication on opiorphin, in 2006, are summarized in this review. Opiorphin is a human endogenous pentapeptide (Gln-Arg-Phe-Ser-Arg) which inhibits both the Neutral EndoPeptidase (NEP) and aminopeptidase N (AP-N), protecting enkephalins from degradation by these ectopeptidases, thus activating endogenous enkephalin-related opioid pathways.
Objective: In this review we highlight the in vitro and in vivo effects of opiorphin.
Results: We examine in detail the structure-activity relationship studies addressed in order to identify the amino acids of opiorphin sequence required to functional interactions with its targets and to design its metabolically stable analogs. The modulation of emotionalrelated behaviors and effects on smooth muscle motility including their resulting therapeutic implication are also analysed. In addition, the in vitro potency of opiorphin and its metabolically stable analogs on opioid receptor binding by enkephalin-related peptides are also summarized. Finally, quantitative or semiquantitative analytical methods of opiorphin on various biological samples are cited.
Conclusion: The advantages and difficulties of therapeutic applications of opiorphin peptide and its synthetic derivatives are discussed.
Export Options
About this article
Cite this article as:
Wollemann Maria and Rougeot Catherine, Human Opiorphin an Endogenous Inhibitor of Enkephalin-Inactivating Ectopeptidases that Displays Antinociception: A Review, Current Bioactive Compounds 2016; 12 (4) . https://dx.doi.org/10.2174/1573407212666160425171005
DOI https://dx.doi.org/10.2174/1573407212666160425171005 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Adenosine Receptors; Potential Clinical Applications
Current Vascular Pharmacology Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey
Current Pharmaceutical Biotechnology The-N-End Rule: The Beginning Determines the End
Protein & Peptide Letters Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry An Evidence-Based Review of Medicinal Plants in the Overall Management of Chronic Fatigue
Current Psychiatry Research and Reviews Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Inflammatory Aspects of Depression
Inflammation & Allergy - Drug Targets (Discontinued) Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Targeting the Role of Astrocytes in the Progression of Alzheimers Disease
Current Signal Transduction Therapy Physiology and Pharmacology of Two-Pore Domain Potassium Channels
Current Pharmaceutical Design Peptide Activators of the p53 Tumor Suppressor
Current Pharmaceutical Design Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease
CNS & Neurological Disorders - Drug Targets White Matter Neuroprotection in Preterm Infants
Current Pediatric Reviews Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Central Nervous System Agents in Medicinal Chemistry SIRT1 Deacetylase Activity and the Maintenance of Protein Homeostasis in Response to Stress: An Overview
Protein & Peptide Letters Preactive Multiple Sclerosis Lesions Offer Novel Clues for Neuroprotective Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Methionine-Independent Translation Initiation from Naturally Occurring Non-AUG Codons
Current Chemical Biology